The pandemic could have permanently improved the definition of success for pharma launches. The outdated model of considering general performance in the first six months isn’t as appropriate anymore, and in many cases the product of comparing launch years may very well be obsolete.Even so, whilst AI can be quite a valuable tool as part of your bl